论文部分内容阅读
目的:观察羟考酮控释片(奥施康定)在中重度癌痛门诊患者个体化治疗中的疗效及安全性。方法:应用羟考酮控释片治疗76例中重度癌痛门诊患者,对其治疗剂量、患者的疼痛缓解情况、生活质量以及不良反应进行观察和评估。结果:76例中重度癌痛门诊患者使用羟考酮控释片的最小剂量为10mg/12h,最大剂量80mg/12h;平均滴定达总有效时间为3.2d(1～11d),疼痛强度评分(NRS)治疗前为6.87±1.25,治疗1周后为2.74±2.30,2周后为2.55±1.21;治疗1周后总有效率为84.2%,2周后为89.5%,治疗前后疼痛强度变化有统计学意义(P<0.01)。治疗前生活质量评分为(49±15)分,治疗2周后为(63±16)分(P<0.05)。用药期间,49例(64.5%)患者曾发生至少一种不良反应,最常见的不良反应依次为便秘44例(57.9%)、嗜睡28例(36.8%)、头晕19例(25.0%)、恶心呕吐17例(22.4%),无1例出现不能耐受的不良反应。结论:羟考酮控释片治疗中重度癌痛门诊患者疗效好,安全性高,给药方便,是治疗中重度癌痛门诊患者的首选药之一。
Objective: To observe the efficacy and safety of oxycodone controlled-release tablets (Oxocydine) in the individualized treatment of patients with moderate-severe cancer pain. Methods: Oxycodone controlled release tablets were used in the treatment of 76 patients with moderate-to-severe cancer pain and outpatients, and their therapeutic dose, pain relief, quality of life and adverse reactions were observed and evaluated. Results: The minimum dose of oxycodone controlled-release tablets was 10mg / 12h and the maximum dose was 80mg / 12h in 76 patients with moderate to severe cancer pain. The total effective time was 3.2d (1 ~ 11d) NRS) was 6.87 ± 1.25 before treatment, 2.74 ± 2.30 after 1 week of treatment and 2.55 ± 1.21 after 2 weeks. The total effective rate was 84.2% after 1 week and 89.5% after 2 weeks. The changes of pain intensity before and after treatment were Statistical significance (P <0.01). The quality of life before treatment was (49 ± 15) minutes and was (63 ± 16) minutes after 2 weeks of treatment (P <0.05). At least one adverse reaction occurred in 49 patients (64.5%) during the course of medication. The most common adverse reactions were constipation in 44 (57.9%), drowsiness in 28 (36.8%), dizziness in 19 (25.0%), nausea Vomiting in 17 cases (22.4%), no case of unacceptable adverse reactions. Conclusion: Oxycodone controlled-release tablets in the treatment of moderate and severe cancer pain clinic patients with good efficacy, high safety, convenient administration, is one of the preferred drug for the treatment of patients with moderate-to-severe cancer pain.